BV6 - CAS:1001600-56-1 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	BV6
英文名称:	BV6
别名:	BV6 (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[(2S)-1-[6-[[(2S)-2-[[(2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3,3-diphenylpropanoyl]amino]hexylamino]-1-oxo-3,3-diphenylpropan-2-yl]pyrrolidine-2-carboxamide
CAS No:	1001600-56-1	分子式:	C₇₀H₉₆N₁₀O₈	分子量:	1205.67
CAS No:	1001600-56-1
分子式:	C₇₀H₉₆N₁₀O₈
分子量:	1205.67

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

B10042 BV6 ≥98%(HPLC) (psaitong)

相关产品

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO(≥58mg/mL)

产品描述：

基本信息

产品编号：B10042
产品名称：BV6
CAS:	1001600-56-1	储存条件	粉末	-20℃	四年

分子式：	C70H96N10O8		溶于液体	-80℃	六个月
分子量	1205.67			-20℃	一个月
化学名：
Solubility (25°C)	体外	DMSO	100mg/mL (82.94mM)
		Ethanol	100mg/mL (82.94mM)
		Water	100mg/mL warmed with 50ºC water bath (82.94mM)
	体内（现配现用）
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	0.8295mL	4.1474mL	8.2948mL
5mM	0.1659mL	0.8295mL	1.6590mL
10mM	0.0829mL	0.4147mL	0.8295mL
50mM	0.0166mL	0.0829mL	0.1659mL

生物活性

产品描述	是凋亡抑制蛋白（IAP），它通过激活NF-κB促进胶质母细胞瘤癌干样细胞分化。
靶点/IC50	cIAP	XIAP
体外研究	HCC193 has an IC50 of 7.2 μM in MTS assays, while H460 cells are not reduced to 50% viability even with 30μM BV6 treatment.Administration of 1μM BV6 to HCC193 cells induces complete depletion of cIAP1 levels at 1 hour post-treatment,while a decrease in XIAP levels is not seen until 24 hours following addition of drug. Similarly, 5μM BV6 fully depletes cIAP1 at 1 hour and begin to reduce XIAP at 24 hours in H460 cells. In parallel findings, cIAP1 levels are decreased in response to a small dose of 0.25μM BV6 in both cell lines, whereas trace amounts of XIAP are still present at 5μM BV6. HCC193 cells demonstrates noticeable cleaved caspase-3 levels beginning 12 hours post-incubation with 1μM BV6, and cleaved caspase-3 levels continued to increase in a time-dependent manner over 48 hours. Treatment of HCC193 cells with 1μM BV6 for 24 hours causes a significant survival curve shift in HCC193 cells relative to DMSO-treated cells, with a DER=1.38 (p<0.05). BV6 (2 and 5µM) significantly represses BrdU incorporation in ectopic and eutopic (disease-free and myomas) ESCs. An ~30% decrease of BrdU incorporation is observed in both groups after treatment with 5µM BV6.
体内研究	Murine cIAP-1, cIAP-2 and XIAP expressions are clearly observed in the cytoplasm of both epithelial and stromal cells of implants,whereas Survivin is mainly expressed in the nuclei BV6 treatment for 4 weeks attenuated the intensity of IAPs expression.The size of lesions range from ~2 to 7 mm in diameter. The monolayer epithelial cell lining of the cyst is shown.After immunohistochemical staining, cytokeratin and vimentin are positively stained, whereas calretinin is negative. After BV6 treatment for 4 weeks, the total number of lesions (4.6 versus 2.8/mouse), the average weight (78.1 versus 32.0mg/mouse) and the surface area (44.5 versus 24.6mm2 /mouse) of lesions are significantly less than in the controls. In the endometrial gland epithelia or stroma, the percentage of Ki67-positive cells decreases after BV6 treatment.

推荐实验方法(仅供参考)

细胞实验:

H460 and HCC193 cell lines are cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cell viability is measured using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay kit. 5000 cells/well are seeded into 96-well plates in triplicate. Following adhesion of cells to the wells, increasing concentrations of BV6 are added into different wells. Control groups are exposed to the same concentration of DMSO. The final concentrations of 333μg/mL MTS and 25μM PMS are added to each well 24 hours later. After two hours incubation at 37℃in humidified 5% CO2, plates are read at the absorbance of 490nm on a microplate reader. Relative cell viability of an individual sample is calculated by normalizing their absorbance to that of the corresponding control.IC50 values are calculated using Prism 5.01. For the TNFα neutralizing antibody assay, cells are exposed to 1 and 5μM BV6 with or without 10μg/mL Infliximab and the assay is performed 24 hours later. Plates are read at the absorbance of 490nm on a microplate reader.

动物实验:

Mice

Female mice (6 weeks of age, BALB/c) are used. All 24 mice are ovariectomized through a 1cm longitudinal skin incision then injected s.c. with estradiol valerate (0.5µg/mouse/week) once per week for 6 weeks until the experimental endometriosis induction. Two weeks after ovariectomy, the uteri of an additional eight donor mice (n=8) are removed en bloc after euthanasia and cleaned of excess tissue in sterile saline. Each uterus is cut to include the uterine horns in each half with a linear incision longitudinally and minced (0.5mm in diameter) with dissecting scissors. The ovariectomized recipient mice (n=16) are anesthetized using pentobarbital sodium. A 0.5cm subabdominal midline incision is made. Each recipient receives half of the donor uterus (1:2 donor uterus to host ratio) minced and added to 500µl saline, and injected into the peritoneal cavity, and the peritoneum is sutured. Injected uterine tissue weighed ~50 mg per mouse. For the next 4 weeks, recipient mice are treated with a single i.p. injection of BV6 (n=8; 10mg/kg) or vehicle (n=8; 1% DMSO) twice weekly.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献